{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:42:16Z","timestamp":1793652136107,"version":"4.5.1"},"reference-count":186,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.critrevonc.2025.104776","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T19:08:25Z","timestamp":1748459305000},"page":"104776","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Cancer in a drop: Advances in liquid biopsy in 2024"],"prefix":"10.1016","volume":"213","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5403-0916","authenticated-orcid":false,"given":"Roberto","family":"Borea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick F.","family":"Saldanha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivahamy","family":"Maheswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Nicolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surbhi","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Pontolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"de Miguel Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Venetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Dipasquale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Ghazali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Pisapia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Ortega","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Gouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0514-0152","authenticated-orcid":false,"given":"Carolina","family":"Reduzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104776_bib1","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/pros.24749","article-title":"LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA","volume":"84","author":"Abramovic","year":"2024","journal-title":"Prostate"},{"key":"10.1016\/j.critrevonc.2025.104776_bib2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/clinchem\/hvad115","article-title":"Classification of brain tumors by nanopore sequencing of cell-free DNA from cerebrospinal fluid","volume":"70","author":"Afflerbach","year":"2024","journal-title":"Clin. Chem."},{"key":"10.1016\/j.critrevonc.2025.104776_bib3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2018.4305","article-title":"Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer","volume":"5","author":"Aggarwal","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2024.106717","article-title":"Mutation detection in saliva from oral cancer patients","volume":"151","author":"Ahmed","year":"2024","journal-title":"Oral. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib5","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1200\/JCO.23.02054","article-title":"Circulating tumor DNA assay detects merkel cell carcinoma recurrence, disease progression, and minimal residual disease: surveillance and prognostic implications","volume":"42","author":"Akaike","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41523-024-00642-6","article-title":"Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients","volume":"10","author":"Alba-Bernal","year":"2024","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.critrevonc.2025.104776_bib7","doi-asserted-by":"crossref","unstructured":"Alkhafaji, S., Wolf, D.M., Magbanua, M.J.M., J. Van \u2018T. Veer, L., Park, J.W., Esserman, L., Mukhtar, R.A., 2024. Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis. npj Breast Cancer 10, 17. https:\/\/doi.org\/10.1038\/s41523-024-00623-9.","DOI":"10.1038\/s41523-024-00623-9"},{"key":"10.1016\/j.critrevonc.2025.104776_bib8","article-title":"Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors \u2013 a biomarker analysis of the ALICE and ICON trials","author":"Andresen","year":"2024","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib9","article-title":"Detection of tumor DNA in bronchoscopic fluids in peripheral NSCLC: a proof-of-concept study","volume":"5","author":"Arhant","year":"2024","journal-title":"JTO Clin. Res Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104776_bib10","first-page":"00081","article-title":"Rationale and design of the COPERNIC trial: a study of on-treatment ctDNA changes in chemo-refractory colorectal cancer patients","volume":"24","author":"Assaf","year":"2024","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.critrevonc.2025.104776_bib11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.annonc.2023.12.006","article-title":"ctDNA quantification improves estimation of outcomes in patients with high-grade osteosarcoma: a translational study from the OS2006 trial","volume":"35","author":"Audinot","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.43392","article-title":"Cost-effectiveness of liquid biopsy for colorectal cancer screening in patients who are unscreened","volume":"6","author":"Aziz","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.critrevonc.2025.104776_bib13","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/cas.16097","article-title":"Beyond blood: advancing the frontiers of liquid biopsy in oncology and personalized medicine","volume":"115","author":"Bao","year":"2024","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2025.104776_bib14","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s00345-024-05287-5","article-title":"Bladder Cancer detection by urinary methylation markers GHSR\/MAL: a validation study","volume":"42","author":"Beijert","year":"2024","journal-title":"World J. Urol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-77781-0","article-title":"Bladder cancer detection in urine by novel methylation markers","volume":"14","author":"Beijert","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2025.104776_bib16","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10549-024-07376-w","article-title":"Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(\u2212) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice","volume":"207","author":"Bhave","year":"2024","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2025.104776_bib17","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1200\/JCO.23.00456","article-title":"Overall survival with circulating tumor cell count\u2013driven choice of therapy in advanced breast cancer: a randomized trial","volume":"42","author":"Bidard","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.critrevonc.2025.104776_bib18","doi-asserted-by":"crossref","first-page":"S1133","DOI":"10.1016\/j.annonc.2024.08.2045","article-title":"1960O Identification of bladder cancer patients that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: preliminary results from the TOMBOLA trial","volume":"35","author":"Bjerggaard Jensen","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib19","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1016\/j.clgc.2023.10.003","article-title":"Urinary miRNAs predict metastasis in patients with clinically localized clear cell renal cell carcinoma treated with nephrectomy","volume":"22","author":"Borges Dos Reis","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104776_bib20","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41698-024-00704-9","article-title":"Longitudinal liquid biopsy predicts clinical benefit from immunotherapy in advanced non-small cell lung cancer","volume":"8","author":"Boscolo Bragadin","year":"2024","journal-title":"NPJ Precis Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216984","article-title":"Prognostic implication of methylation-based circulating tumor DNA detection prior to surgery in stage I non-small cell lung cancer","volume":"594","author":"Boss\u00e9","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2025.104776_bib22","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/oncolo\/oyae155","article-title":"Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma","volume":"29","author":"Botta","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2025.104776_bib23","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1158\/0008-5472.CAN-23-0860","article-title":"The deep learning framework iCanTCR enables early cancer detection using the t-cell receptor repertoire in peripheral blood","volume":"84","author":"Cai","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104776_bib24","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1158\/0008-5472.CAN-23-3486","article-title":"Multidimensional fragmentomics enables early and accurate detection of colorectal cancer","volume":"84","author":"Cao","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104776_bib25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00401-018-1879-y","article-title":"Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience","volume":"136","author":"Capper","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib26","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.ccell.2024.06.003","article-title":"Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution","volume":"42","author":"Casanova-Salas","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2025.104776_bib27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41698-024-00541-w","article-title":"Sequencing of cerebrospinal fluid cell-free DNA facilitated early differential diagnosis of intramedullary spinal cord tumors","volume":"8","author":"Chai","year":"2024","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib28","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/ijc.34981","article-title":"Fragmentomics features of ovarian cancer","volume":"155","author":"Chao","year":"2024","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104776_bib29","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1007\/s12072-024-10680-8","article-title":"Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma","volume":"18","author":"Chuma","year":"2024","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.critrevonc.2025.104776_bib30","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.annonc.2024.08.2334","article-title":"Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS\/BRAFV600E wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial","volume":"35","author":"Ciardiello","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib31","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1158\/1078-0432.CCR-23-2326","article-title":"Comparison of circulating tumor DNA assays for molecular residual disease detection in early-stage triple-negative breast cancer","volume":"30","author":"Coakley","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104776_bib32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13148-024-01696-w","article-title":"Diagnosis of pediatric central nervous system tumors using methylation profiling of cfDNA from cerebrospinal fluid","volume":"16","author":"Cornelli","year":"2024","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.critrevonc.2025.104776_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103687","article-title":"Association of post-operative ctDNA detection with outcomes of patients with early breast cancers","volume":"9","author":"Cutts","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2025.104776_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1480302","article-title":"Longitudinal detection of somatic mutations in the saliva of head and neck squamous cell carcinoma-affected patients: a pilot study","volume":"14","author":"Dal Secco","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib35","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41392-021-00647-8","article-title":"Molecular mechanisms underpinning sarcomas and implications for current and future therapy","volume":"6","author":"Damerell","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.critrevonc.2025.104776_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2024.100161","article-title":"Early monitoring of plasma KRAS G12C with digital PCR predicts antitumor response to immunotherapy or sotorasib in advanced NSCLC: a brief report","volume":"6","author":"De Giglio","year":"2024","journal-title":"J. Liq. Biopsy"},{"key":"10.1016\/j.critrevonc.2025.104776_bib37","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.31722","article-title":"Circulating tumor DNA and survival in metastatic breast cancer: a systematic review and meta-analysis","volume":"7","author":"Dickinson","year":"2024","journal-title":"JAMA Netw. Open"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104776_bib38","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00718","article-title":"Improving prediction of survival and progression in metastatic non-small cell lung cancer after immunotherapy through machine learning of circulating tumor DNA","author":"Ding","year":"2024","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib39","doi-asserted-by":"crossref","first-page":"6862","DOI":"10.1038\/s41467-024-51316-7","article-title":"Identifying key circulating tumor DNA parameters for predicting clinical outcomes in metastatic non-squamous non-small cell lung cancer after first-line chemoimmunotherapy","volume":"15","author":"Ding","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.104776_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2024.100272","article-title":"Liquid biopsy through non-blood fluids: the show must go on","volume":"6","author":"Dipasquale","year":"2024","journal-title":"J. Liq. Biopsy"},{"key":"10.1016\/j.critrevonc.2025.104776_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12419","article-title":"Extracellular vesicles as a promising source of lipid biomarkers for breast cancer detection in blood plasma","volume":"13","author":"Dorado","year":"2024","journal-title":"J. Extracell. Vesicle"},{"key":"10.1016\/j.critrevonc.2025.104776_bib42","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3390\/cancers16050978","article-title":"Circular STAG2 RNA modulates bladder cancer progression via miR-145-5p\/TAGLN2 and is considered as a biomarker for recurrence","volume":"16","author":"Du","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104776_bib43","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s00432-022-04034-w","article-title":"Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach","volume":"149","author":"Englmeier","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1323226","article-title":"A real-world clinicopathological model for predicting pathological complete response to neoadjuvant chemotherapy in breast cancer","volume":"14","author":"Fang","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib45","unstructured":"FDA, 2016. cobas EGFR Mutation Test v2. cobas EGFR Mutation Test v2. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/cobas-egfr-mutation-test-v2."},{"key":"10.1016\/j.critrevonc.2025.104776_bib46","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/clinchem\/hvad144","article-title":"Efficacy of lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells\u2014the DETECT III clinical trial","volume":"70","author":"Fehm","year":"2024","journal-title":"Clin. Chem."},{"key":"10.1016\/j.critrevonc.2025.104776_bib47","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.annonc.2024.05.541","article-title":"Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA","volume":"35","author":"Felip","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib48","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/s41467-024-45475-w","article-title":"Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer","volume":"15","author":"Fonseca","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.104776_bib49","doi-asserted-by":"crossref","first-page":"7187","DOI":"10.1097\/JS9.0000000000001906","article-title":"Clinical significance of circulating tumor cells in colorectal cancer with peritoneal metastases: a prospective cohort study using a novel method for monitoring treatment response, and assessing minimal residual disease","volume":"110","author":"Fr\u00fchling","year":"2024","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.critrevonc.2025.104776_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1325157","article-title":"The long noncoding RNA SUMO1P3 as urinary biomarker for monitoring bladder cancer progression","volume":"14","author":"Galbiati","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib51","article-title":"Resectable non-small cell lung cancer heterogeneity and recurrence assessed by tissue next-generation sequencing genotyping and circulating tumor cell EZH2 characterization","author":"Garcia-Diaz","year":"2024","journal-title":"Arch. De. Bronconeumol. \u00eda"},{"key":"10.1016\/j.critrevonc.2025.104776_bib52","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10549-024-07508-2","article-title":"Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer","volume":"209","author":"Garcia-Murillas","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2025.104776_bib53","article-title":"Circulating tumor DNA: a new research frontier in urological oncology from localized to metastatic disease","author":"Garofoli","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103978","article-title":"Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients","volume":"9","author":"Genta","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2025.104776_bib55","doi-asserted-by":"crossref","unstructured":"Germani, M.M., Vetere, G., Giordano, M., Cirac\u00ec, P., Capone, I., Tamborini, E., Conca, E., Busico, A., Pietrantonio, F., Piva, V.M., Boccaccino, A., Simionato, F., Bortolot, M., Manca, P., Lonardi, S., Conca, V., Borelli, B., Carullo, M., Del Re, M., Fontanini, G., Rossini, D., Cremolini, C., 2023. Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial. Front Oncol 13, 1307545. https:\/\/doi.org\/10.3389\/fonc.2023.1307545.","DOI":"10.3389\/fonc.2023.1307545"},{"key":"10.1016\/j.critrevonc.2025.104776_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217325","article-title":"Integrating machine learning-predicted circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in metastatic breast cancer: a proof of principle study on endocrine resistance profiling","volume":"609","author":"Gerratana","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2025.104776_bib57","article-title":"Prognostic significance of circulating and disseminated tumor cells in breast cancer patients before and after adjuvant chemotherapy","volume":"26","author":"Ghaffari","year":"2024","journal-title":"Cell J."},{"key":"10.1016\/j.critrevonc.2025.104776_bib58","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s13046-024-03105-9","article-title":"Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients","volume":"43","author":"Giordani","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104776_bib59","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10549-024-07366-y","article-title":"Measuring cfDNA integrity as a biomarker for predicting neoadjuvant chemotherapy response in breast cancer patients: a pilot study","volume":"206","author":"Giro","year":"2024","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2025.104776_bib60","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.37871","article-title":"Circulating tumor cell count and overall survival in patients with metastatic hormone-sensitive prostate cancer","volume":"7","author":"Goldkorn","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.critrevonc.2025.104776_bib61","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/17476348.2024.2423824","article-title":"Recent advances in the use of liquid biopsy for the diagnosis and treatment of lung cancer","volume":"18","author":"Gristina","year":"2024","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.critrevonc.2025.104776_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.aca.2024.343452","article-title":"Luminol\/PtCo@rGO and Au@CNTs-based electrochemiluminescence cytosensor for ultrasensitive detection of breast cancer CTCs","volume":"1335","author":"Guo","year":"2025","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.critrevonc.2025.104776_bib63","first-page":"63","article-title":"Circulating tumor DNA as prognostic markers of relapsed breast cancer: a systematic review and meta-analysis","volume":"4","author":"Guo","year":"2024","journal-title":"J. Natl. Cancer Cent."},{"key":"10.1016\/j.critrevonc.2025.104776_bib64","first-page":"153","article-title":"The prognostic role of circulating tumor DNA across breast cancer molecular subtypes: a systematic review and meta-analysis","volume":"4","author":"Guo","year":"2024","journal-title":"J. Natl. Cancer Cent."},{"key":"10.1016\/j.critrevonc.2025.104776_bib65","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.annonc.2024.04.012","article-title":"A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results","volume":"35","author":"Hamilton","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib66","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/s12916-024-03620-8","article-title":"Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1\/2 LASER201 study","volume":"22","author":"Han","year":"2024","journal-title":"BMC Med."},{"key":"10.1016\/j.critrevonc.2025.104776_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2023.07.011","article-title":"The rare circulating tumor microemboli as a biomarker contributes to predicting early colorectal cancer recurrences after medical treatment","volume":"263","author":"Hao","year":"2024","journal-title":"Transl. Res."},{"key":"10.1016\/j.critrevonc.2025.104776_bib68","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.annonc.2024.01.003","article-title":"Longitudinal profiling identifies co-occurring BRCA1\/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer","volume":"35","author":"Harvey-Jones","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.suronc.2024.102060","article-title":"Association of preoperative and postoperative circulating tumour DNA (ctDNA) with PIK3CA gene mutation with risk of recurrence in patients with non-metastatic breast cancer","volume":"54","author":"Hassan","year":"2024","journal-title":"Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib70","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3892\/mco.2024.2727","article-title":"Circulating tumor DNA serial monitoring of relapse and responses to tislelizumab immunotherapy as second\u2011line monotherapy for metastatic esophageal squamous cell carcinoma: a prospective study","volume":"20","author":"He","year":"2024","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib71","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03577-y","article-title":"Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB\u2013IIIA non-small-cell lung cancer","author":"Herbst","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.104776_bib72","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s40478-024-01846-4","article-title":"Real-world experience with circulating tumor DNA in cerebrospinal fluid from patients with central nervous system tumors","volume":"12","author":"Hickman","year":"2024","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.critrevonc.2025.104776_bib73","article-title":"Personalized MRD assessment in peri-surgical ctDNA for prognostic prediction in hepatocellular carcinoma","author":"Hu","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104776_bib74","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12967-024-04989-z","article-title":"High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study","volume":"22","author":"Huang","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2025.104776_bib75","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2340\/1651-226X.2024.25581","article-title":"KIDNEY-PAGER: analysis of circulating tumor DNA as a biomarker in renal cancer - an observational trial. Study protocol","volume":"63","author":"Iisager","year":"2024","journal-title":"Acta Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib76","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13058-024-01823-8","article-title":"NSABP FB-10: a phase Ib\/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer","volume":"26","author":"Jacobs","year":"2024","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104776_bib77","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41523-024-00611-z","article-title":"Predicting response to neoadjuvant chemotherapy with liquid biopsies and multiparametric MRI in patients with breast cancer","volume":"10","author":"Janssen","year":"2024","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.critrevonc.2025.104776_bib78","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1038\/s41591-022-02047-z","article-title":"Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer","volume":"28","author":"Jee","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.104776_bib79","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1200\/JCO.24.00110","article-title":"Phase I\/Ib trial of inavolisib plus palbociclib and endocrine therapy for PIK3CA -mutated, hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative advanced or metastatic breast cancer","volume":"42","author":"Jhaveri","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.critrevonc.2025.104776_bib80","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1093\/oncolo\/oyad195","article-title":"Association of FTH1-expressing circulating tumor cells with efficacy of neoadjuvant chemotherapy for patients with breast cancer: a prospective cohort study","volume":"29","author":"Jia","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2025.104776_bib81","article-title":"Plasma circulating tumor DNA unveils the efficacy of PD-1 inhibitors and chemotherapy in advanced gastric cancer","volume":"14","author":"Jiang","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2025.104776_bib82","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3390\/diagnostics14050468","article-title":"Hypermethylation Loci of ZNF671, IRF8, and OTX1 as potential urine-based predictive biomarkers for bladder cancer","volume":"14","author":"Jiang","year":"2024","journal-title":"Diagnostics"},{"key":"10.1016\/j.critrevonc.2025.104776_bib83","doi-asserted-by":"crossref","first-page":"132","DOI":"10.23922\/jarc.2023-051","article-title":"Monitoring ctDNA RAS mutational status in metastatic colorectal cancer: a trial protocol of RAS-trace and RAS-trace-2 studies","volume":"8","author":"Kataoka","year":"2024","journal-title":"J. Anus Rectum Colon"},{"key":"10.1016\/j.critrevonc.2025.104776_bib84","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41591-024-02877-z","article-title":"Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses","volume":"30","author":"Kelly","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.104776_bib85","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41591-024-02877-z","article-title":"Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses","volume":"30","author":"Kelly","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.104776_bib86","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.7150\/thno.99245","article-title":"Tumor-derived EV miRNA signatures surpass total EV miRNA in supplementing mammography for precision breast cancer diagnosis","volume":"14","author":"Kim","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.critrevonc.2025.104776_bib87","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s40478-024-01887-9","article-title":"Detection of diagnostic somatic copy number alterations from cerebrospinal fluid cell-free DNA in brain tumor patients","volume":"12","author":"Klinsing","year":"2024","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.critrevonc.2025.104776_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2024.116839","article-title":"Ultrasensitive detection of cancer-associated nucleic acids and mutations by primer exchange reaction-based signal amplification and flow cytometry","volume":"267","author":"Kocabey","year":"2025","journal-title":"Biosens. Bioelectron."},{"key":"10.1016\/j.critrevonc.2025.104776_bib89","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.21873\/anticanres.17044","article-title":"PIK3CA hotspot mutations in saliva as a diagnostic marker in oral squamous cell carcinoma patients","volume":"44","author":"Kr\u00fcger","year":"2024","journal-title":"Anticancer Res"},{"key":"10.1016\/j.critrevonc.2025.104776_bib90","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.3390\/cells13221884","article-title":"Circulating micro-RNAs predict the risk of recurrence in triple-negative breast cancer","volume":"13","author":"Kujala","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2025.104776_bib91","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/cas.16104","article-title":"Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer","volume":"115","author":"Lee","year":"2024","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2025.104776_bib92","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1158\/1078-0432.CCR-19-0624","article-title":"Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer","volume":"25","author":"Leighl","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104776_bib93","article-title":"Digital quantitative detection for heterogeneous protein and mRNA expression patterns in circulating tumor cells","volume":"12","author":"Li","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.critrevonc.2025.104776_bib94","doi-asserted-by":"crossref","first-page":"16227","DOI":"10.1021\/acs.analchem.4c02914","article-title":"Interpretable machine learning-aided optical deciphering of serum exosomes for early detection, staging, and subtyping of lung cancer","volume":"96","author":"Liu","year":"2024","journal-title":"Anal. Chem."},{"key":"10.1016\/j.critrevonc.2025.104776_bib95","article-title":"Cerebrospinal fluid ctDNA testing shows an advantage over plasma ctDNA testing in advanced non-small cell lung cancer patients with brain metastases","volume":"13","author":"Liu","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib96","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1002\/1878-0261.13745","article-title":"Transformer-based representation learning and multiple-instance learning for cancer diagnosis exclusively from raw sequencing fragments of bisulfite-treated plasma cell-free DNA","volume":"18","author":"Liu","year":"2024","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110330","article-title":"Prostate cancer detection through unbiased capture of methylated cell-free DNA","volume":"27","author":"Lleshi","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.critrevonc.2025.104776_bib98","doi-asserted-by":"crossref","first-page":"S1268","DOI":"10.1016\/j.annonc.2023.10.020","article-title":"LBA28 The PEGASUS trial: post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients","volume":"34","author":"Lonardi","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib99","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1158\/1078-0432.CCR-24-0268","article-title":"Plasma versus tissue tumor mutational burden as biomarkers of durvalumab plus tremelimumab response in patients with metastatic colorectal cancer in the CO.26 trial","volume":"30","author":"Loree","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104776_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2024.126907","article-title":"Four-dimensional trapped ion mobility spectrometry proteomics reveals circulating extracellular vesicles encapsulated drivers of nasopharyngeal carcinoma distant dissemination","volume":"282","author":"Lu","year":"2025","journal-title":"Talanta"},{"key":"10.1016\/j.critrevonc.2025.104776_bib101","doi-asserted-by":"crossref","unstructured":"MacManus, D., 2023. Melanoma (staging), in:Radiopaedia.Org. Radiopaedia.org. https:\/\/doi.org\/10.53347\/rID-171950.","DOI":"10.53347\/rID-171950"},{"key":"10.1016\/j.critrevonc.2025.104776_bib102","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1158\/1078-0432.CCR-23-2928","article-title":"Cell-free DNA concentration as a biomarker of response and recurrence in HER2-negative breast cancer receiving neoadjuvant chemotherapy","volume":"30","author":"Magbanua","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104776_bib103","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1186\/s12967-024-05783-7","article-title":"Monitoring circulating tumor DNA liquid biopsy in stage III BRAF-mutant melanoma patients undergoing adjuvant treatment","volume":"22","author":"Marchisio","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2025.104776_bib104","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jmoldx.2024.08.011","article-title":"Surveillance of disease progression in metastatic breast cancer by molecular counting of circulating tumor DNA using plasma-seqsensei breast cancer in vitro diagnostics assay","volume":"27","author":"Martens","year":"2025","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.critrevonc.2025.104776_bib105","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jtcvs.2024.01.017","article-title":"Early real-world experience monitoring circulating tumor DNA in resected early-stage non-small cell lung cancer","volume":"168","author":"Martin","year":"2024","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.critrevonc.2025.104776_bib106","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1158\/2159-8290.CD-24-0519","article-title":"Clinical validation of a cell-free DNA fragmentome assay for augmentation of lung cancer early detection","volume":"14","author":"Mazzone","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2025.104776_bib107","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/clinchem\/hvae156","article-title":"Machine learning-based detection of bladder cancer by urine cfDNA fragmentation hotspots that capture cancer-associated molecular features","volume":"70","author":"Meng","year":"2024","journal-title":"Clin. Chem."},{"key":"10.1016\/j.critrevonc.2025.104776_bib108","article-title":"Noninvasive multicancer detection using DNA hypomethylation of LINE-1 retrotransposons","author":"Michel","year":"2024","journal-title":"Clin. Cancer Res. OF1\u2013OF17"},{"key":"10.1016\/j.critrevonc.2025.104776_bib109","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00432-023-05594-1","article-title":"Short-term serial circulating tumor DNA assessment predicts therapeutic efficacy for patients with advanced pancreatic cancer","volume":"150","author":"Motobayashi","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104776_bib110","doi-asserted-by":"crossref","DOI":"10.1200\/PO.24.00216","article-title":"Early circulating tumor DNA shedding kinetics for prediction of platinum sensitivity in patients with small cell lung cancer","author":"Murciano-Goroff","year":"2024","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102390","article-title":"Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis","volume":"9","author":"Nader-Marta","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2025.104776_bib112","article-title":"A tumor-na\u00efve ctDNA assay detects minimal residual disease in resected stage II or III colorectal cancer and predicts recurrence: subset analysis from the GALAXY study in CIRCULATE-Japan","author":"Nakamura","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104776_bib113","article-title":"Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors","author":"Nakamura","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.104776_bib114","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1158\/1078-0432.CCR-24-1651","article-title":"Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease assay","volume":"30","author":"Nakamura","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104776_bib115","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1038\/s41591-024-03254-6","article-title":"ctDNA-based molecular residual disease and survival in resectable colorectal cancer","volume":"30","author":"Nakamura","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.104776_bib116","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ijc.34978","article-title":"Gene expression markers in peripheral blood and outcome in patients with platinum-resistant ovarian cancer: a study of the European GANNET53 consortium","volume":"155","author":"Obermayr","year":"2024","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104776_bib117","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11060-023-04555-5","article-title":"Reliable detection of genetic alterations in cyst fluid DNA for the diagnosis of brain tumors","volume":"166","author":"On","year":"2024","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib118","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1158\/1078-0432.CCR-22-2903","article-title":"Liquid biopsy of cerebrospinal fluid enables selective profiling of glioma molecular subtypes at first clinical presentation","volume":"29","author":"Orzan","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104776_bib119","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41571-024-00967-y","article-title":"Minimal residual disease as a target for liquid biopsy in patients with solid tumours","volume":"22","author":"Pantel","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib120","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13058-024-01768-y","article-title":"c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive\/HER2-negative metastatic breast cancer","volume":"26","author":"Park","year":"2024","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104776_bib121","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s11864-024-01180-w","article-title":"Circulating tumor DNA (ctDNA) and its role in gynecologic malignancies","volume":"25","author":"Pomerantz","year":"2024","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib122","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","article-title":"Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"85","author":"Powles","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib123","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1038\/s41591-024-03091-7","article-title":"Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial","volume":"30","author":"Powles","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.104776_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2024.116968","article-title":"Detection of brain metastases from blood using Brain nanoMET sensor: extracellular vesicles as a dynamic marker for metastatic brain tumors","volume":"269","author":"Premachandran","year":"2025","journal-title":"Biosens. Bioelectron."},{"key":"10.1016\/j.critrevonc.2025.104776_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.113687","article-title":"Circulating tumor cells reveal early predictors of disease progression in patients with stage III NSCLC undergoing chemoradiation and immunotherapy","volume":"43","author":"Purcell","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.critrevonc.2025.104776_bib126","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1111\/cas.16284","article-title":"Plasma cell-free DNA methylome-based liquid biopsy for accurate gastric cancer detection","volume":"115","author":"Qi","year":"2024","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2025.104776_bib127","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.cllc.2022.11.007","article-title":"Liquid biopsy versus tissue biopsy to determine front line therapy in metastatic non-small cell lung cancer (NSCLC)","volume":"24","author":"Raez","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.critrevonc.2025.104776_bib128","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-24-0013","article-title":"Novel combinations of immunotherapies or DNA damage repair inhibitors in platinum-refractory extensive-stage small cell lung cancer: the phase II BALTIC study","volume":"30","author":"Reinmuth","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104776_bib129","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.3390\/cancers16172990","article-title":"Expression analysis of circulating microRNAs in saliva and plasma for the identification of clinically relevant biomarkers for oral squamous cell carcinoma and oral potentially malignant disorders","volume":"16","author":"Rocchetti","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104776_bib130","doi-asserted-by":"crossref","first-page":"8851","DOI":"10.1038\/s41467-024-53145-0","article-title":"Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp","volume":"15","author":"Rodrigues","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.104776_bib131","article-title":"Liquid biopsy in progressing prostate cancer patients starting docetaxel with or without enzalutamide: a biomarker study of the PRESIDE phase 3b trial","author":"Ruiz-Vico","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2024.100156","article-title":"The role of liquid biopsy as a catalyst for sustained progress in precision oncology \u2013 perspective of the young committee of the international society of liquid biopsy","volume":"5","author":"Saldanha","year":"2024","journal-title":"J. Liq. Biopsy"},{"key":"10.1016\/j.critrevonc.2025.104776_bib133","doi-asserted-by":"crossref","first-page":"S306","DOI":"10.1016\/j.annonc.2024.08.2230","article-title":"226TiP CLEAR-Me: interception trial to detect and clear molecular residual disease in patients with high-risk melanoma","volume":"35","author":"Saldanha","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib134","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00230","article-title":"Circulating and imaging biomarkers of radium-223 response in metastatic castration-resistant prostate cancer","author":"Saylor","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib135","doi-asserted-by":"crossref","unstructured":"Schraa, S.J., Van Rooijen, K.L., Van Der Kruijssen, D.E.W., Rubio Alarc\u00f3n, C., Phallen, J., Sausen, M., Simmons, J., Coup\u00e9, V.M.H., Van Grevenstein, W.M.U., Elias, S., Verkooijen, H.M., Lacl\u00e9, M.M., Bosch, L.J.W., Van Den Broek, D., Meijer, G.A., Velculescu, V.E., Fijneman, R.J.A., Vink, G.R., Koopman, M., And on behalf of the PLCRC-MEDOCC group, Dunker, M.S., Lutke Holzik, M.F., Hoekstra, R., Sommeijer, D.W., Van Der Bilt, J.D.W., Consten, E.C.J., Cirkel, G.A., Burghgraef, T.A., Van Der Schans, E.M., Nieboer, P., Rietbroek, R.C., Dekker, J.W.T., Verschoor, A.J., Talsma, K.A.K., Brosens, R.P.M., Helgason, H.H., Marinelli, A.W.K.S., De Hingh, I.H.J.T., Oldenhuis, C.N., Jansen, J., Van Halteren, H.K., Stockmann, H.B.A.C., Beeker, A., Bosscha, K., Pruijt, H.F.M., Spierings, L.E.A.M.M., Valkenburg-Van Iersel, L.B.J., Vles, W.J., De Jongh, F.E., Van Cruijsen, H., Heikens, J.T., Zimmerman, D.D.E., Van Alphen, R.J., Schiphorst, A.H.W., Van Leeuwen-Snoeks, L.L., Vogelaar, J.F.J., Peters, N.A.J.B., 2020. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study. BMC Cancer 20, 790. https:\/\/doi.org\/10.1186\/s12885-020-07252-y.","DOI":"10.1186\/s12885-020-07252-y"},{"key":"10.1016\/j.critrevonc.2025.104776_bib136","doi-asserted-by":"crossref","first-page":"8750","DOI":"10.1038\/s41467-024-52923-0","article-title":"Tumour-informed liquid biopsies to monitor advanced melanoma patients under immune checkpoint inhibition","volume":"15","author":"Schroeder","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.104776_bib137","article-title":"Association of tumor-informed circulating tumor DNA detectability before and after radical cystectomy with disease-free survival in patients with bladder cancer","author":"Sfakianos","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib138","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3390\/life14081024","article-title":"Methylated DNA markers in voided urine for the identification of clinically significant prostate cancer","volume":"14","author":"Shah","year":"2024","journal-title":"Life"},{"key":"10.1016\/j.critrevonc.2025.104776_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2024.100168","article-title":"Circulating tumor DNA fraction predicts residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer","volume":"6","author":"Shan","year":"2024","journal-title":"J. Liq. Biopsy"},{"key":"10.1016\/j.critrevonc.2025.104776_bib140","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00456","article-title":"Serial postoperative circulating tumor DNA assessment has strong prognostic value during long-term follow-up in patients with breast cancer","author":"Shaw","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib141","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-023-02791-w","article-title":"Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer","volume":"30","author":"Shitara","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.104776_bib142","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-53223-3","article-title":"HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01","volume":"15","author":"Siena","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.104776_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102879","article-title":"Cerebrospinal fluid tumor DNA for liquid biopsy in glioma patients\u2019 management: close to the clinic?","volume":"146","author":"Simonelli","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib144","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1158\/1078-0432.CCR-24-0226","article-title":"Tissue-free liquid biopsies combining genomic and methylation signals for minimal residual disease detection in patients with early colorectal cancer from the UK TRACC Part B study","volume":"30","author":"Slater","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104776_bib145","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41551-021-00837-3","article-title":"Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics","volume":"6","author":"Song","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.critrevonc.2025.104776_bib146","doi-asserted-by":"crossref","first-page":"10079","DOI":"10.3390\/ijms251810079","article-title":"Extracellular RNAs from whole urine to distinguish prostate cancer from benign prostatic hyperplasia","volume":"25","author":"Stella","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.104776_bib147","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70216","article-title":"Combination of circulating tumor cells and 18F - FDG PET \/ CT for precision diagnosis in patients with non-small cell lung cancer","volume":"13","author":"Sun","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2025.104776_bib148","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1158\/1078-0432.CCR-24-1096","article-title":"Circulating tumor DNA assessment for treatment monitoring adds value to PSA in metastatic castration-resistant prostate cancer","volume":"30","author":"Sweeney","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104776_bib149","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1136\/ijgc-2024-005313","article-title":"Circulating tumor DNA as a biomarker for predicting progression-free survival and overall survival in patients with epithelial ovarian cancer: a systematic review and meta-analysis","volume":"34","author":"Taliento","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104776_bib150","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/cas.16025","article-title":"Postoperative recurrence detection using individualized circulating tumor DNA in upper tract urothelial carcinoma","volume":"115","author":"Tamura","year":"2024","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2025.104776_bib151","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/cncr.35263","article-title":"Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer","volume":"130","author":"Tan","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2025.104776_bib152","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1186\/s12951-024-02863-0","article-title":"The new advance of exosome-based liquid biopsy for cancer diagnosis","volume":"22","author":"Tang","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib153","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1111\/cas.14926","article-title":"CIRCULATE-Japan: circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer","volume":"112","author":"Taniguchi","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2025.104776_bib154","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejca.2022.08.016","article-title":"Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: a systematic review","volume":"175","author":"Tesileanu","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104776_bib155","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/1759-7714.15251","article-title":"Postoperative ctDNA in indicating the recurrence risk and monitoring the effect of adjuvant therapy in surgical non-small cell lung cancer","volume":"15","author":"Tian","year":"2024","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104776_bib156","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.euo.2023.08.009","article-title":"Early on-treatment circulating tumor DNA measurements and response to immune checkpoint inhibitors in advanced urothelial cancer","volume":"7","author":"Tolmeijer","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103684","article-title":"Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing","volume":"9","author":"Triner","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2025.104776_bib158","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/s41416-023-02446-0","article-title":"Liquid biopsy: creating opportunities in brain space","volume":"129","author":"Trivedi","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104776_bib159","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-based therapy in PIK3CA -mutated advanced breast cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104776_bib160","unstructured":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research., Celebrex NDA 20998\/S007 approval letter, 2024. FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer."},{"key":"10.1016\/j.critrevonc.2025.104776_bib161","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1002\/1878-0261.12574","article-title":"Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions","volume":"13","author":"Villatoro","year":"2019","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib162","doi-asserted-by":"crossref","DOI":"10.1097\/SLA.0000000000006562","article-title":"Mutant KRAS in circulating tumor DNA as a biomarker in localized pancreatic cancer in patients treated with neoadjuvant chemotherapy","author":"Vitello","year":"2024","journal-title":"Ann. Surg."},{"key":"10.1016\/j.critrevonc.2025.104776_bib163","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1007\/s12094-024-03422-7","article-title":"Plasma ctDNA enhances the tissue-based detection of oncodriver mutations in colorectal cancer","volume":"26","author":"Wang","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib164","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102126","article-title":"Circulating exosomal protein EFEMP1 and SERPINC1 as diagnostic biomarkers for epithelial ovarian cancer","volume":"50","author":"Wang","year":"2024","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103738","article-title":"Early evaluation of circulating tumor DNA as marker of therapeutic efficacy and prognosis in breast cancer patients during primary systemic therapy","volume":"76","author":"Wang","year":"2024","journal-title":"Breast"},{"key":"10.1016\/j.critrevonc.2025.104776_bib166","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1186\/s12885-024-12913-3","article-title":"A urine-based liquid biopsy for detection of upper tract urothelial carcinoma: a self-matched study","volume":"24","author":"Wei","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2025.104776_bib167","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10147-023-02435-6","article-title":"Diagnosis of colorectal cancer based on folate receptor-positive circulating tumor cell analysis: a retrospective cohort study","volume":"29","author":"Wei","year":"2024","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104776_bib168","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2379864","article-title":"Results of a phase I\/IIa trial of SV-BR-1-GM inoculation with low-dose cyclophosphamide and interferon alpha (Bria-IMT) in metastatic breast cancer","volume":"20","author":"Wiseman","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.critrevonc.2025.104776_bib169","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1111\/cas.16106","article-title":"Alix-normalized exosomal programmed death-ligand 1 analysis in urine enables precision monitoring of urothelial cancer","volume":"115","author":"Woo","year":"2024","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2025.104776_bib170","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1039\/D4AN00460D","article-title":"A quadratic isothermal amplification fluorescent biosensor without intermediate purification for ultrasensitive detection of circulating tumor DNA","volume":"149","author":"Wu","year":"2024","journal-title":"Analyst"},{"key":"10.1016\/j.critrevonc.2025.104776_bib171","doi-asserted-by":"crossref","first-page":"7255","DOI":"10.1038\/s41467-024-51536-x","article-title":"Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study","volume":"15","author":"Xu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.104776_bib172","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1158\/0008-5472.CAN-23-3998","article-title":"Proteomic profiling of serum extracellular vesicles identifies diagnostic signatures and therapeutic targets in breast cancer","volume":"84","author":"Xu","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104776_bib173","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/cas.16360","article-title":"Evaluation of cfDNA fragmentation characteristics in plasma for the diagnosis of lung cancer: a prospective cohort study","volume":"116","author":"Xu","year":"2025","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2025.104776_bib174","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2147\/BCTT.S478328","article-title":"Plasma exosome miR-203a-3p is a potential liquid biopsy marker for assessing tumor progression in breast cancer patients","volume":"16","author":"Yang","year":"2024","journal-title":"BCTT"},{"key":"10.1016\/j.critrevonc.2025.104776_bib175","doi-asserted-by":"crossref","first-page":"17679","DOI":"10.1021\/acs.analchem.4c03726","article-title":"Diagnosis and biomarker screening of endometrial cancer enabled by a versatile exosome metabolic fingerprint platform","volume":"96","author":"Yang","year":"2024","journal-title":"Anal. Chem."},{"key":"10.1016\/j.critrevonc.2025.104776_bib176","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.4143\/crt.2023.1371","article-title":"Evaluation of molecular residual disease by a fixed panel in resectable colorectal cancer","volume":"56","author":"Yang","year":"2024","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2025.104776_bib177","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-70887-5","article-title":"Longitudinal dynamics of circulating tumor DNA for treatment monitoring in patients with breast cancer recurrence","volume":"14","author":"Yoo","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2025.104776_bib178","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13073-024-01352-1","article-title":"Multi-dimensional cell-free DNA-based liquid biopsy for sensitive early detection of gastric cancer","volume":"16","author":"Yu","year":"2024","journal-title":"Genome Med."},{"key":"10.1016\/j.critrevonc.2025.104776_bib179","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41523-023-00607-1","article-title":"Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment","volume":"10","author":"Zaikova","year":"2024","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.critrevonc.2025.104776_bib180","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cllc.2023.09.008","article-title":"Adjuvant therapy-free strategy for stage IB to IIIA non-small-cell lung cancer patients after radical resection based on longitudinal undetectable molecular residual disease: prospective, multicenter, single-arm study (CTONG 2201)","volume":"25","author":"Zhang","year":"2024","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.critrevonc.2025.104776_bib181","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102774","article-title":"Liquid biopsy: an arsenal for tumour screening and early diagnosis","volume":"129","author":"Zhang","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2025.104776_bib182","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adp1704","article-title":"Multiplex digital profiling of DNA methylation heterogeneity for sensitive and cost-effective cancer detection in low-volume liquid biopsies","volume":"10","author":"Zhao","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.critrevonc.2025.104776_bib183","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2024.120026","article-title":"Highly specific multiplex DNA methylation detection for liquid biopsy of colorectal cancer","volume":"565","author":"Zhu","year":"2025","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.critrevonc.2025.104776_bib184","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2024.116411","article-title":"High-throughput enrichment of portal venous circulating tumor cells for highly sensitive diagnosis of CA19-9-negative pancreatic cancer patients using inertial microfluidics","volume":"259","author":"Zhu","year":"2024","journal-title":"Biosens. Bioelectron."},{"key":"10.1016\/j.critrevonc.2025.104776_bib185","doi-asserted-by":"crossref","DOI":"10.34133\/research.0431","article-title":"Liquid biopsy instrument for ultra-fast and label-free detection of circulating tumor cells","volume":"7","author":"Zhu","year":"2024","journal-title":"Research"},{"key":"10.1016\/j.critrevonc.2025.104776_bib186","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70346","article-title":"A novel urine DNA predictor for noninvasive early diagnosis and monitoring minimal residual disease of upper tract urothelial carcinoma","volume":"13","author":"Zuo","year":"2024","journal-title":"Cancer Med."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:29:14Z","timestamp":1762352954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825001647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":186,"alternative-id":["S1040842825001647"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104776","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer in a drop: Advances in liquid biopsy in 2024","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104776","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104776"}}